Sonic Healthcare +24.85% Gain

The Fund focuses on Australian and United States large cap securities and ETFs, to deliver superior risk adjusted investment returns.

Our unique point of difference is our proprietary algorithm-based investment models which are designed to quantify market momentum and remove much of the emotional human bias in the investment decision-making process.

Two classes of units in the Fund are offered

Class A Units – which provide investment exposure to ASX listed securities and exchange traded funds.

Class B Units – which provide investment exposure to United States listed securities and exchange traded funds.

For more information, please call 1300 614 002.

Sonic Healthcare – Buy

Sonic Healthcare 1H21 Revenue $4.4bn, up 33% on the same time last year. EBITDA increased to $1.02bn and further growth of 5 – 10% into FY22 underpins our buy recommendation.

The balance sheet remains under-geared and we expect to see the company actively seeking M&A or JV opportunities.

SHL trades on a forward yield of 3.8%